TransCode Therapeutics (NASDAQ: RNAZ), a clinical-stage company developing immuno-oncology and RNA-based therapeutics for high-risk and advanced cancers, released clinical data from its Phase 1a trial of TTX-MC138 in poster 1025P at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain. The ongoing multicenter, open-label study evaluates safety, tolerability, pharmacokinetics, antitumor activity and exploratory biomarkers in patients with previously treated advanced solid tumors.
TTX-MC138 was administered once every 28 days across four dose levels ranging from 0.8 mg/kg to 4.8 mg/kg. The trial met its primary safety endpoint, with no dose-limiting toxicities observed and dose-dependent plasma exposure demonstrated across all evaluated doses. The company also reported disease stabilization and extended progression-free intervals in a subset of patients, supporting continued clinical evaluation of TTX-MC138.
The results matter because TTX-MC138 targets microRNA-10b, a well-documented biomarker of metastasis, in patients whose tumors overexpress it. Demonstrating safety and dose-dependent exposure in this first-in-human study clears a key hurdle for RNA-based therapeutics, which have historically faced delivery and tolerability challenges. The absence of dose-limiting toxicities across all four dose levels suggests a favorable safety profile that could support dose escalation and combination strategies in future trials.
For TransCode, the data provide early clinical validation of its lead candidate and its broader pipeline of immuno-oncology and RNA therapeutics. The company noted that disease stabilization and extended progression-free intervals in a subset of patients, while preliminary, support continued clinical evaluation. Investors and clinicians will look for larger patient numbers and longer follow-up to confirm whether the signals translate into meaningful clinical benefit.
The full press release is available at https://ibn.fm/g3E2F. The latest news and updates relating to RNAZ are available in the company’s newsroom at https://ibn.fm/RNAZ.
The announcement was distributed through InvestorWire, a specialized communications platform focused on wire-grade press release syndication. InvestorWire is one of more than 75 brands within the Dynamic Brand Portfolio at IBN, which provides services including editorial syndication to 5,000+ outlets and social media distribution. Full terms of use and disclaimers applicable to all content provided by InvestorWire are available at https://www.InvestorWire.com/Disclaimer.
